Press Releases

You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.

Continue

News Search

Financial Releases
Corporate Releases
Product Releases

December
- December 21, 2001
  
  OSI Pharmaceuticals and Gilead Sciences Announce Closing of Oncology Assets Deal
November
- November 28, 2001
  
  Gilead Begins Phase I Study of GS7904L, an Investigational Anticancer Drug
- November 26, 2001
  
  OSI Pharmaceuticals Acquires Oncology Assets from Gilead Sciences
- November 13, 2001
  
  Gilead Begins Phase I Study of GS7836, an Investigational Anticancer Drug
- November 13, 2001
  
  Gilead Announces Data from Studies of Adefovir Dipivoxil in Patients with Lamivudine-Resistant Chronic Hepatitis B Virus Infection
- November 12, 2001
  
  Gilead Announces Data from Studies of Adefovir Dipivoxil Demonstrating Significant Improved Liver Function and Viral Load Reduction in Patients with Chronic Hepatitis B Virus Infection
- November 09, 2001
  
  Gilead Announces Primary Endpoint Met in Phase III Study of Adefovir Dipivoxil 10 mg in Patients with Lamivudine-Resistant Chronic Hepatitis B Infection
October
- October 26, 2001
  
  U.S. FDA Approves Gilead Sciences’ Anti-HIV Drug Viread™
- October 25, 2001
  
  Gilead Sciences Announces Third Quarter 2001 Financial Results
- October 25, 2001
  
  Gayle Edlund Wilson Joins Gilead Sciences Board of Directors
- October 23, 2001
  
  Gilead Licenses Rights Under Its Selex and Aptamer Patent Estate to Archemix
- October 18, 2001
  
  European CPMP Gives Positive Opinion on Viread™, Gilead’s New Once-Daily Treatment for HIV Infection
- October 03, 2001
  
  Gilead Announces FDA Advisory Committee Supports Use of Viread™ in Treatment-Experienced Patients with HIV Infection
- October 02, 2001
  
  FDA Posts Background Documents for October 3 Viread™ Advisory Committee Meeting
September
- September 25, 2001
  
  Gilead’s Investigational Antiretroviral Agent Viread™ Reduces Viral Load in HIV Patients with Resistant Virus in Pivotal Phase III Study
- September 19, 2001
  
  Gilead Sciences Announces Results From Phase III Study of Adefovir Dipivoxil In Precore Mutant Chronic Hepatitis B Virus Infection
- September 06, 2001
  
  Gilead Sciences Announces Acceptance of Late Breaker Abstract at Upcoming ICAAC Meeting
August
- August 22, 2001
  
  Gilead Sciences Announces Degussa Corporation Will Acquire Gilead's 49 Percent Interest in Proligo L.L.C.
- August 21, 2001
  
  Gilead’s Viread™ for the Treatment of HIV Infection to be Reviewed by FDA Antiviral Advisory Committee on October 3, 2001
July
- July 26, 2001
  
  Gilead Sciences Announces Second Quarter 2001 Financial Results
June
May
- May 04, 2001
  
  Gilead Sciences Submits Marketing Authorisation Application to European Regulatory Authorities for Tenofovir DF for the Treatment of HIV Infection
- May 01, 2001
  
  Gilead Sciences Submits New Drug Application to U.S. FDA for Tenofovir DF for the Treatment of HIV Infection
April
- April 26, 2001
  
  Gilead Sciences Announces First Quarter 2001 Financial Results
- April 24, 2001
  
  Gilead Sciences Broadens Entry Criteria for Tenofovir DF Expanded Access Program in the United States
- April 23, 2001
  
  Gilead Sciences Announces Data from Studies of Adefovir Dipivoxil, Investigational Agent for the Treatment of Chronic Hepatitis B Infection
- April 18, 2001
  
  Cordell W. Hull Joins Gilead Sciences Board of Directors
February
- February 27, 2001
  
  Roche Submits Oral Flu Drug Tamiflu for Regulatory Approval in Europe
- February 20, 2001
  
  Gilead Sciences Announces Preliminary Results from Phase III Study of Investigational Anti-HIV Agent Tenofovir DF
- February 14, 2001
  
  JAMA Study Reveals Roche's Tamiflu™ Effective In Protecting People Exposed to Influenza
- February 02, 2001
  
  Gilead Sciences Stockholders Clear the Way for 2-for-1 Stock Split
January
- January 31, 2001
  
  Gilead Announces Start of Early Access Program for Investigational Anti-HIV Agent Tenofovir DF in United States and France
- January 25, 2001
  
  Gilead Sciences Announces Fourth Quarter and Year End 2000 Financial Results
- January 22, 2001
  
  Gilead Board of Directors Appoints James M. Denny as Chairman
- January 19, 2001
  
  Gilead Sciences to Release Fourth Quarter and Year-End 2000 Earnings on Thursday, January 25, 2001
- January 19, 2001
  
  Gilead Board of Directors Approves Two-For-One Stock Split
- January 18, 2001
  
  Pharmacy Shelves Make Room for Tamiflu™ Liquid for Kids
- January 16, 2001
  
  Gilead Sciences and GlaxoSmithKline Modify Terms of License Agreement for NX 211, Gilead's Investigational Compound for the Treatment of Cancer
- January 07, 2001
  
  Cubist Pharmaceuticals and Gilead Sciences Announce European Commercialization Agreement for Investigational Antibacterial Agent Cidecin™

At Gilead we are inspired by the opportunity to address unmet medical needs for patients living with life-threatening diseases around the world.

December

November

October

September

August

July

June

May

April

February

January